RxDoctor Payments Data

Monica Brown, DO

Internal Medicine · Stuart, FLNPI 1952756900

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 32 payments — averaging $55.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$604
  • AstraZeneca$224
  • Abbott$170
  • Lilly USA, LLC$144
  • Pfizer$143
  • Relievant Medsystems, Inc.$136
  • plus $339 from 5 others

What the payments were for

  • Food & beverage$1,760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,760 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$8,760
Medicare patients
31
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$114,944
OzempicSemaglutide80$114,330
JardianceEmpagliflozin59$81,901
XareltoRivaroxaban34$32,585
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$22,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$21,135
MounjaroTirzepatide12$14,652
EntrestoSacubitril/Valsartan11$13,249
MyrbetriqMirabegron12$12,495
Spiriva RespimatTiotropium Bromide16$12,287
Dabigatran EtexilateDabigatran Etexilate Mesylate22$7,311
Tresiba Flextouch U-100Insulin Degludec15$6,885
Rosuvastatin Calcium406$4,679
Atorvastatin Calcium486$4,467
Celecoxib113$4,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$114,94492 claims
Novo NordiskOzempic$604$114,33080 claims
AstraZenecaBreztri Aerosphere$224$22,72831 claims
GSKTrelegy Ellipta$128$21,13520 claims
Lilly USA, LLCMounjaro$144$14,65212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →